Table 3.
Therapeutic efficacy of AFP S-ODNs in SMMC-7721 hepatoma bearing nude mice
| Group (mg/day × day) |
Mean tumor weight (mg) |
Toxic deaths | AFP content (% inhibition) | |||||||
| 0* | 2 | 4 | 6 | 8 | 10 | 12 | 14 | |||
| Control (0) | 96.7 ± 51.1 | 191.4 ± 48.3 | 336.9 ± 67.8 | 504.8 ± 80.2 | 636.3 ± 68.8 | 823.9 ± 187.6 | 1056.7 ± 182.0 | 1201.6 ± 208.0 | 0/6 | - |
| Antisense (0.25 ± 8) | 83.1 ± 33.7 | 145.2 ± 43.8 (24.2) | 215.8 ± 49.6 (35.9)a | 286.5 ± 49.2 (43.2)a | 356.7 ± 52.5 (43.9)a | 520.0 ± 56.1 (36.9)a | 653.1 ± 128.8 (38.2)a | 776.6 ± 61.3 (35.4)a | 0/6 | 68.9a |
| Antisense (0.50 ± 8) | 84.8 ± 34.6 | 130.3 ± 36.9 (31.9)a | 202.3 ± 47.9 (39.9)a | 254.2 ± 43.2 (49.6)a | 310.8 ± 56.9 (51.2)a | 449.9 ± 108.3 (45.4)a | 593.9 ± 72.3 (43.8)a | 737.3 ± 146.7 (38.6)a | 0/6 | 73.8a |
| Sense (0.25 ± 8) | 100.5 ± 33.5 | 201.4 ± 44.2 | 339.1 ± 71.1 | 510.4 ± 114.1 | 629.6 ± 109.4 | 829.5 ± 164.5 | 1034.9 ± 198.1 | 1191.9 ± 181.3 | 0/6 | 3.4 |
| Sense (0.50 ± 8) | 86.9 ± 25.6 | 187.7 ± 42.3 | 359.7 ± 59.6 | 509.5 ± 111.8 | 659.7 ± 101.7 | 837.7 ± 147.3 | 1011.0 ± 142.9 | 1232.3 ± 149.0 | 0/6 | 0 |
Mice were treated the eighth day after tumor cell implantation with S-ODNs following different schedules. Untreated mice received normal saline only. *Time after S-ODN administration (day). Values in parentheses: percent inhibition. Each value represents mean ± SD of 6 samples.
a
P < 0.05 (Mann-Whitney U test) compared with untreated mice and mice treated with sense S-ODNs.